Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tonkin

Showing results (331-340 of 338) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 338 results.
Stroke|September 21, 2020
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI SubstudyMukul Sharma, Robert G Hart, Eric E Smith, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|July 31, 2018
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trialMukul Sharma, Robert G Hart, Eric E Smith, et al.
Nature|October 19, 2017
Molecular basis of USP7 inhibition by selective small-molecule inhibitorsAndrew P Turnbull, Stephanos Ioannidis, Wojciech W Krajewski, et al.
Gastroenterology|June 2, 2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or AspirinPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
Gastroenterology|May 6, 2019
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled TrialPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
The New England Journal of Medicine|August 29, 2017
Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseJohn W Eikelboom, Stuart J Connolly, Jackie Bosch, et al.
JAMA|May 13, 2024
Prognostic Value of Cardiovascular Biomarkers in the PopulationJohannes Tobias Neumann, Raphael Twerenbold, Jessica Weimann, et al.
The Canadian Journal of Cardiology|July 30, 2017
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) TrialJackie Bosch, John W Eikelboom, Stuart J Connolly, et al.
Pageof 34

Showing results (331-340 of 338) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 338 results.
Stroke|September 21, 2020
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI SubstudyMukul Sharma, Robert G Hart, Eric E Smith, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|July 31, 2018
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trialMukul Sharma, Robert G Hart, Eric E Smith, et al.
Nature|October 19, 2017
Molecular basis of USP7 inhibition by selective small-molecule inhibitorsAndrew P Turnbull, Stephanos Ioannidis, Wojciech W Krajewski, et al.
Gastroenterology|June 2, 2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or AspirinPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
Gastroenterology|May 6, 2019
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled TrialPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
The New England Journal of Medicine|August 29, 2017
Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseJohn W Eikelboom, Stuart J Connolly, Jackie Bosch, et al.
JAMA|May 13, 2024
Prognostic Value of Cardiovascular Biomarkers in the PopulationJohannes Tobias Neumann, Raphael Twerenbold, Jessica Weimann, et al.
The Canadian Journal of Cardiology|July 30, 2017
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) TrialJackie Bosch, John W Eikelboom, Stuart J Connolly, et al.
Pageof 34